AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22949149 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose (≥ 30 Gy) thoracic radiation (n = 38)
Number of subjects: 62
Study 22949149 — intervention group
Group type: COMPARATOR
Intervention: Lower-dose (< 30 Gy) thoracic radiation combined with anthracycline (n = 24)
Number of subjects: 62
Study 22949149 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher thoracic radiation dose
Number of subjects: 62
Study 22949149 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivors with leukoencephalopathy
Number of subjects: 62
Study 22949149 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory impairment
Number of subjects: 62
Study 22949149 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurocognitive performance
Number of subjects: 62
Study 20589590 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration Group (n=12, static and dynamic exercises on a vibration plate, frequency: 15-25 Hz, amplitude: 2-12.8 cm)
Number of subjects: 38
Study 20589590 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Group (n=16, same exercises without vibration)
Number of subjects: 38
Study 20589590 — intervention group
Group type: COMPARATOR
Intervention: Control Group (n=10)
Number of subjects: 38
Study 17606723 — intervention group
Group type: EXPERIMENTAL
Intervention: i.p. catumaxomab (5 to 200 microg)
Number of subjects: 23
Study 15749317 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime administered intravascularly as a bolus dose of 1.5 g
Number of subjects: 17
Study 15749317 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 17
Study 12218843 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (Project SAFE)
Number of subjects: 249
Study 12218843 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 249
Study 10544396 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1%
Number of subjects: 117
Study 10544396 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 2%
Number of subjects: 117
Study 8508193 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO) condition with increased carbohydrate intake from 5.8 to 8.8 g kg‐1 BW, supplemented with a 16.5% glucose polymer solution.
Number of subjects: 16
Study 8508193 — intervention group
Group type: COMPARATOR
Intervention: Control (C) group with an isocaloric diet, additional energy from fat and protein.
Number of subjects: 16
Study 3691011 — intervention group
Group type: EXPERIMENTAL
Intervention: Unflavored oral suspension (20 mg/mL)
Number of subjects: 12
Study 3691011 — intervention group
Group type: COMPARATOR
Intervention: Tablets (two 200-mg tablets)
Number of subjects: 12
Study 3691011 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavored and unflavored carbamazepine suspensions
Number of subjects: 12
Study 30557965 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose MDCT (ldMDCT)
Number of subjects: 288
Study 30557965 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose MDCT (sdMDCT)
Number of subjects: 288
Study 27420732 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Level Laser Therapy (LLLT) with a 940 nm diode laser, energy of 4 J/cm² applied to one side immediately after surgery
Number of subjects: 35
Study 27420732 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no laser energy applied)
Number of subjects: 35
Study 25142813 — intervention group
Group type: EXPERIMENTAL
Intervention: Edaravone (intravenous 30 mg twice per day for 2 weeks)
Number of subjects: 137
Study 22692521 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal collagen cross-linking (CXL)
Number of subjects: 76
Study 20651094 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fluoride dentifrice
Number of subjects: 0
Study 20651094 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional dentifrice
Number of subjects: 0
Study 17873681 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine plus rivastigmine
Number of subjects: 122
Study 17873681 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine alone
Number of subjects: 122
Study 17873681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 17873681 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine plus fluoxetine
Number of subjects: 122
Study 16149837 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital photographic technique for measuring head shapes
Number of subjects: 60
Study 16149837 — intervention group
Group type: COMPARATOR
Intervention: Flexicurve ruler for measuring head shapes
Number of subjects: 60
Study 16149837 — intervention group
Group type: EXPERIMENTAL
Intervention: Oblique cranial length ratio
Number of subjects: 60
Study 16149837 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalic index
Number of subjects: 60
Study 12131309 — intervention group
Group type: EXPERIMENTAL
Intervention: Periprostatic nerve block
Number of subjects: 100
Study 12131309 — intervention group
Group type: COMPARATOR
Intervention: No anesthesia
Number of subjects: 100
Study 10520836 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. pantoprazole (20, 40, 80, or 120 mg)
Number of subjects: 39
Study 10520836 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. pantoprazole (80 and 120 mg)
Number of subjects: 39
Study 10520836 — intervention group
Group type: COMPARATOR
Intervention: i.v. famotidine (20 mg)
Number of subjects: 39
Study 10520836 — intervention group
Group type: COMPARATOR
Intervention: saline placebo
Number of subjects: 39
Study 8730940 — intervention group
Group type: EXPERIMENTAL
Intervention: Public education campaign (didactic component)
Number of subjects: 0
Study 8730940 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational campaign)
Number of subjects: 0
Study 1757751 — intervention group
Group type: EXPERIMENTAL
Intervention: PlanAlyzer interactive program for anemia diagnosis
Number of subjects: 328
Study 1757751 — intervention group
Group type: COMPARATOR
Intervention: Traditional textual materials for anemia diagnosis
Number of subjects: 328
Study 7064850 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg)
Number of subjects: 21
Study 7064850 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol (100 mg)
Number of subjects: 21
Study 7064850 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined nifedipine and acebutolol
Number of subjects: 21
Study 31756383 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based cognitive behavioral pain management intervention (WebMAP)
Number of subjects: 260
Study 31756383 — intervention group
Group type: COMPARATOR
Intervention: Web-based pain education program (WebED)
Number of subjects: 260
Study 30624952 — intervention group
Group type: EXPERIMENTAL
Intervention: Sardinian folk dance (Ballu Sardu, BS)
Number of subjects: 20
Study 30624952 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 20
Study 28807845 — intervention group
Group type: EXPERIMENTAL
Intervention: Real 1-Hz rTMS (2000 stimuli, 110% motor threshold)
Number of subjects: 163
Study 28807845 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 163
Study 28807845 — intervention group
Group type: EXPERIMENTAL
Intervention: Real 1-Hz rTMS
Number of subjects: 163
Study 28807845 — intervention group
Group type: COMPARATOR
Intervention: Real 1-Hz rTMS and Sham rTMS
Number of subjects: 163
Study 25504267 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadripolar lead
Number of subjects: 418
Study 25504267 — intervention group
Group type: COMPARATOR
Intervention: Bipolar lead
Number of subjects: 418
Study 23085503 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (initial dose of 50mg once daily, with dose escalation to a maximum of 200mg)
Number of subjects: 200
Study 23085503 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo to sertraline)
Number of subjects: 200
Study 23085503 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 200
Study 21821474 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 400
Study 21821474 — intervention group
Group type: EXPERIMENTAL
Intervention: Watchful waiting
Number of subjects: 400
Study 21821474 — intervention group
Group type: COMPARATOR
Intervention: Population-based control group
Number of subjects: 400
Study 19196887 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 69
Study 19196887 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 69
Study 17468863 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod 6 mg, twice daily
Number of subjects: 90
Study 17468863 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod 6 mg, twice daily plus esomeprazole 40 mg, once daily
Number of subjects: 90
Study 17468863 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 40 mg, once daily
Number of subjects: 90
Study 14735174 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral topotecan
Number of subjects: 190
Study 14735174 — intervention group
Group type: COMPARATOR
Intervention: Infusion topotecan
Number of subjects: 190
Study 11504276 — intervention group
Group type: COMPARATOR
Intervention: FFR‐rFVIIa (0.01, 0.02, 0.05, 0.08, 0.12, 0.18, 0.27, or 0.40 mg/kg body weight)
Number of subjects: 62
Study 11504276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 9737352 — intervention group
Group type: EXPERIMENTAL
Intervention: Menatetrenone (MK-4) 45 mg daily for 12 months
Number of subjects: 108
Study 9737352 — intervention group
Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 108
Study 9495218 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) treatment
Number of subjects: 85
Study 1983508 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) Fragmin
Number of subjects: 90
Study 1983508 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin Calciparin
Number of subjects: 90
Study 304126 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (332 patients)
Number of subjects: 686
Study 304126 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment (354 patients)
Number of subjects: 686
Study 304126 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (in patients with left main disease)
Number of subjects: 686
Study 304126 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (in patients with triple vessel disease)
Number of subjects: 686
Study 31896431 — intervention group
Group type: EXPERIMENTAL
Intervention: Grocery shopping skill program (8 sessions)
Number of subjects: 20
Study 31896431 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation (wait-list group)
Number of subjects: 20
Study 31842969 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medicine (CM), 10 g/packet, twice daily for 2 weeks
Number of subjects: 378
Study 31842969 — intervention group
Group type: COMPARATOR
Intervention: CM placebo, 10 g/packet, twice daily for 2 weeks
Number of subjects: 378
Study 28288296 — intervention group
Group type: EXPERIMENTAL
Intervention: ProNamel®
Number of subjects: 20
Study 28288296 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth Mousse™
Number of subjects: 20
Study 28288296 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study 25521535 — intervention group
Group type: EXPERIMENTAL
Intervention: everolimus
Number of subjects: 300
Study 25521535 — intervention group
Group type: COMPARATOR
Intervention: CsA
Number of subjects: 300
Study 23871490 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 year of trastuzumab
Number of subjects: 5102
Study 23871490 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 years of trastuzumab
Number of subjects: 5102
Study 23871490 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 5102
Study 21792500 — intervention group
Group type: EXPERIMENTAL
Intervention: Cementless total hip arthroplasty
Number of subjects: 250
Study 21792500 — intervention group
Group type: COMPARATOR
Intervention: Cemented total hip arthroplasty
Number of subjects: 250
Study 19234715 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing arm-cranking (grinding)
Number of subjects: 33
Study 17921553 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol
Number of subjects: 58
Study 17921553 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 58
Study 17921553 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone + Glycerol
Number of subjects: 58
Study 17921553 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 15264186 — intervention group
Group type: EXPERIMENTAL
Intervention: HD with HF80(S)
Number of subjects: 14
Study 15264186 — intervention group
Group type: EXPERIMENTAL
Intervention: HD with FX80
Number of subjects: 14
Study 15264186 — intervention group
Group type: EXPERIMENTAL
Intervention: postdilution HDF, 20 L, with FX80
Number of subjects: 14
Study 15264186 — intervention group
Group type: EXPERIMENTAL
Intervention: predilution HDF, 20 L, with FX80
Number of subjects: 14
Study 15264186 — intervention group
Group type: EXPERIMENTAL
Intervention: predilution HDF, 60 L, with FX80
Number of subjects: 14
Study 15264186 — intervention group
Group type: EXPERIMENTAL
Intervention: HDF
Number of subjects: 14
Study 15264186 — intervention group
Group type: COMPARATOR
Intervention: High‐flux HD
Number of subjects: 14
Study 11578788 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin plus vitamin C and vitamin E
Number of subjects: 1007
Study 11578788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1007
Study 9745160 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: DeNol 120 mg, amoxicillin 500 mg and metronidazole 250 mg four times a day orally for 14 days
Number of subjects: 90
Study 9745160 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: omeprazole 20 mg plus clarithromycin 500 mg twice a day and amoxicillin 500 mg four times a day for 14 days
Number of subjects: 90
Study 9745160 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C: omeprazole 20 mg, clarithromycin 250 mg and metronidazole 500 mg twice a day for seven days
Number of subjects: 90
Study 7990079 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II (5 ng/kg/min) infusion for three hours
Number of subjects: 5
Study 7990079 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 5
Study 3198000 — intervention group
Group type: EXPERIMENTAL
Intervention: ICS 205-930, 20 mg
Number of subjects: 12
Study 3198000 — intervention group
Group type: COMPARATOR
Intervention: ICS 205-930, 10 mg
Number of subjects: 12
Study 31877381 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyst-like component of subchondral BMLs
Number of subjects: 50
Study 31877381 — intervention group
Group type: EXPERIMENTAL
Intervention: Synovial tissue volume (STV)
Number of subjects: 50
Study 31877381 — intervention group
Group type: EXPERIMENTAL
Intervention: Total subchondral BML volume
Number of subjects: 50
Study 31877381 — intervention group
Group type: EXPERIMENTAL
Intervention: Total ligament-based BML volume
Number of subjects: 50
Study 31877381 — intervention group
Group type: EXPERIMENTAL
Intervention: Subchondral BMLs with cyst-like component
Number of subjects: 50
Study 30213849 — intervention group
Group type: EXPERIMENTAL
Intervention: 89Zr-deferoxamine-ZEGFR:03115 (2.4-3.6 MBq, 2 μg) co-injected with 10 μg of nonlabeled ZEGFR:03115
Number of subjects: 0
Study 30213849 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F-aluminium fluoride-NOTA-ZEGFR:03115 (12 μg, 1.5-2 MBq/mouse)
Number of subjects: 0
Study 30213849 — intervention group
Group type: EXPERIMENTAL
Intervention: PET imaging data
Number of subjects: 0
Study 30213849 — intervention group
Group type: EXPERIMENTAL
Intervention: PET analysis
Number of subjects: 0
Study 29285569 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 45
Study 29285569 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 25319131 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound treatment (US) at 1 MHz, intensity of 1.5 W/cm², continuous mode, applied five times a week for 2 weeks
Number of subjects: 32
Study 25319131 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) at 0.8 J/cm² with 905 nm wavelength, applied five times a week for 2 weeks
Number of subjects: 32
Study 23294481 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental education regarding changing to reduced-fat dairy foods
Number of subjects: 133
Study 23294481 — intervention group
Group type: COMPARATOR
Intervention: Comparison non-dietary behaviour
Number of subjects: 133
Study 20921291 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol with lanthanum carbonate (3000 mg/day)
Number of subjects: 41
Study 20921291 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol with sevelamer carbonate (7200 mg/day)
Number of subjects: 41
Study 20921291 — intervention group
Group type: COMPARATOR
Intervention: Calcitriol alone
Number of subjects: 41
Study 18850485 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG plus mitral valve correction
Number of subjects: 550
Study 18850485 — intervention group
Group type: COMPARATOR
Intervention: CABG alone
Number of subjects: 550
Study 16720937 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercises for dorsiflexors (4 sets of 10 isometric contractions at 60% of MVC, 3X/week for 8 weeks)
Number of subjects: 10
Study 16720937 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercises for dorsiflexors
Number of subjects: 10
Study 15127672 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics as recommended by National Institute for Clinical Excellence guidelines
Number of subjects: 0
Study 11744561 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 614
Study 11744561 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole
Number of subjects: 614
Study 9403370 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching mental state understanding tasks to children with autism
Number of subjects: 0
Study 9403370 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 8465360 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg daily
Number of subjects: 1473
Study 8465360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1473
Study 3898818 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg at night (hs)
Number of subjects: 143
Study 3898818 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily (bid)
Number of subjects: 143
Study 30387869 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-implant mandibular overdenture (SIMO)
Number of subjects: 34
Study 30387869 — intervention group
Group type: COMPARATOR
Intervention: Conventional complete denture (CD)
Number of subjects: 34
Study 29468383 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral levocarnitine solution (50-100 mg/kg/day)
Number of subjects: 29
Study 29468383 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (oral hydrochlorothiazide, enalapril, spironolactone; digoxin for NYHA grade IV; dopamine and dobutamine for intractable heart failure; metoprolol when cardiac function restored to NYHA grade II-III)
Number of subjects: 29
Study 26751937 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate (NIT) supplementation
Number of subjects: 20
Study 26751937 — intervention group
Group type: EXPERIMENTAL
Intervention: NIT
Number of subjects: 20
Study 26751937 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 20
Study 26751937 — intervention group
Group type: COMPARATOR
Intervention: PLA
Number of subjects: 20
Study 24111854 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D animation
Number of subjects: 68
Study 24111854 — intervention group
Group type: COMPARATOR
Intervention: Control (narration and drawing)
Number of subjects: 68
Study 22331280 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental muscle pain (induced by intramuscular injections of hypertonic (6%) saline)
Number of subjects: 15
Study 22331280 — intervention group
Group type: COMPARATOR
Intervention: Control (isotonic (0.9%) saline injections)
Number of subjects: 15
Study 20565454 — intervention group
Group type: EXPERIMENTAL
Intervention: IK-1001 (Na2S) 0.005-0.20 mg kg(-1), i.v., infused over 1 min
Number of subjects: 0
Study 20565454 — intervention group
Group type: EXPERIMENTAL
Intervention: Na2S (sodium sulphide)
Number of subjects: 0
Study 17077114 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtenon injection of triamcinolone acetonide (TA) before laser grid pattern photocoagulation (G‐PC)
Number of subjects: 37
Study 17077114 — intervention group
Group type: COMPARATOR
Intervention: Laser grid pattern photocoagulation (G‐PC) without TA injection
Number of subjects: 37
Study 17077114 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtenon injection of triamcinolone acetonide (TA) before G‐PC
Number of subjects: 37
Study 15995772 — intervention group
Group type: EXPERIMENTAL
Intervention: Periocline administered subgingivally at baseline and weeks 1 to 4
Number of subjects: 0
Study 15995772 — intervention group
Group type: COMPARATOR
Intervention: Control group (no drug administered)
Number of subjects: 0
Study 11955734 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined radiotherapy and adjuvant chemotherapy (9 weekly cycles of 24-h infusional chemotherapy: 20 mg/m² cisplatin, 2,200 mg/m² 5-fluorouracil, and 120 mg/m² leucovorin) after RT
Number of subjects: 154
Study 11955734 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (35-40 fractions, 1.8-2.0 Gy/fraction/day, 5 days/week, total dose 70-72 Gy)
Number of subjects: 154
Study 9434653 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice guidelines
Number of subjects: 54
Study 9434653 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 54
Study 8568015 — intervention group
Group type: COMPARATOR
Intervention: Nefazodone single daily doses (5-500 mg)
Number of subjects: 17
Study 8568015 — intervention group
Group type: COMPARATOR
Intervention: Nefazodone multiple daily doses (5 mg or 10 mg 3 times a day to a maximum of 500 mg 3 times a day)
Number of subjects: 17
Study 8568015 — intervention group
Group type: COMPARATOR
Intervention: Nefazodone maximum tolerated level (up to 1350 mg total daily dose)
Number of subjects: 17
Study 8568015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 2564834 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (100 micrograms/h after a 250 microgram bolus for the first two days)
Number of subjects: 71